Seeking Clues to Hologic (HOLX) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics

In its upcoming report, Hologic (HOLX) is predicted by Wall Street analysts to post quarterly earnings of $1.05 per share, reflecting a decline of 0.9% compared to the same period last year. Revenues are forecasted to be $1.01 billion, representing a year-over-year decrease of 0.4%.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.Given this perspective, it's time to examine the average forecasts of specific Hologic metrics that are routinely monitored and predicted by Wall Street analysts.The combined assessment of analysts suggests that 'Revenues- GYN surgical' will likely reach $179.82 million. The estimate points to a change of +7.9% from the year-ago quarter.Based on the collective assessment of analysts, 'Revenues- Diagnostics- Molecular diagnostics' should arrive at $316.12 million. The estimate points to a change of +1.8% from the year-ago quarter.It is projected by analysts that the 'Revenues- Diagnostics- Blood screening' will reach $5.65 million. The estimate indicates a year-over-year change of -28.5%.Analysts expect 'Revenues- Breast health- Breast imaging' to come in at $277.39 million. The estimate indicates a change of -10.3% from the prior-year quarter.Analysts predict that the 'Revenues- Total Diagnostics' will reach $437.46 million. The estimate suggests a change of -0.8% year over year.The consensus among analysts is that 'Revenues- Skeletal health' will reach $25.34 million. The estimate points to a change of +33.4% from the year-ago quarter.Analysts forecast 'Revenues- Diagnostics- Cytology and perinatal' to reach $117.36 million. The estimate indicates a year-over-year change of -4%.According to the collective judgment of analysts, 'Revenues- Total Breast health' should come in at $363.15 million. The estimate points to a change of -5.7% from the year-ago quarter.The consensus estimate for 'Revenues- Breast health- Interventional breast solutions' stands at $85.76 million. The estimate indicates a year-over-year change of +13.1%.The average prediction of analysts places 'Revenues- Service and other' at $202.73 million. The estimate indicates a year-over-year change of +1.3%.Analysts' assessment points toward 'Revenues- Product' reaching $801.50 million. The estimate points to a change of -1.2% from the year-ago quarter. View all Key Company Metrics for Hologic here>>> Hologic shares have witnessed a change of +1.5% in the past month, in contrast to the Zacks S&P 500 composite's +4.6% move. With a Zacks Rank #4 (Sell), HOLX is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .#1 Semiconductor Stock to Buy (Not NVDA)The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hologic, Inc. (HOLX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks